BIOMAT Database Logo BIOMAT Database Logo

Pharmacologic antagonism of thromboxane A2 receptors by trimetoquinol analogs in vitro and in vivo. 1991

Y Shin, and K J Romstedt, and K Doyle, and M W Harrold, and M A Gerhardt, and D D Miller, and P N Patil, and D R Feller
Division of Pharmacology, College of Pharmacy, Ohio State University, Columbus 43210.

Although (-)-(S)-trimetoquinol [1-(3,4,5-trimethoxy-benzyl)- 6,7-dihydroxy-1,2,3,4-tetrahydroisoquinoline; TMQ] is recognized as a potent bronchodilator, (+)-(R)-TMQ is a selective antagonist of human platelet aggregation and serotonin secretion induced by thromboxane A2 (TXA2) agonists. To confirm the pharmacological actions of TMQ analogs, the interaction of the drugs with TXA2 receptors was examined in human platelets and in a mouse sudden death model. The inhibitory potencies of TMQ analogs (pIC50 values) for displacement of [3H]SQ 29,548 binding to platelets showed excellent correlation with the respective pIC50 (-log IC50) values for U46619-induced aggregation (r = 0.99, P less than 0.01) and serotonin secretion (r = 0.99, P less than 0.01) in human platelet-rich plasma and for whole blood aggregation (r = 0.99, P less than 0.01). In each system, the rank order of inhibitory potencies was rac-iodoTMQ greater than or equal to (+)-(R)-TMQ greater than rac-TMQ much greater than (-)-(S)-TMQ. Antithrombotic effects of TMQ analogs were evaluated in a mouse sudden death model. In vivo antithrombotic potencies of these compounds were consistent with the in vitro potencies as TXA2 receptor antagonists in platelet systems. Administration of rac-iodoTMQ, (+)-(R)-TMQ and rac-TMQ 15 min before the injection of U46619 (800 micrograms/kg, iv) protected mice against U46619-induced sudden death. On the other hand, (-)-(S)-TMQ did not protect animals against death. Protection of U46619-induced cardiopulmonary thrombosis by TMQ analogs was seen at doses of 3-100 mg/kg.(ABSTRACT TRUNCATED AT 250 WORDS)

UI MeSH Term Description Entries
D008297 Male Males
D010974 Platelet Aggregation The attachment of PLATELETS to one another. This clumping together can be induced by a number of agents (e.g., THROMBIN; COLLAGEN) and is part of the mechanism leading to the formation of a THROMBUS. Aggregation, Platelet
D011450 Prostaglandin Endoperoxides, Synthetic Synthetic compounds that are analogs of the naturally occurring prostaglandin endoperoxides and that mimic their pharmacologic and physiologic activities. They are usually more stable than the naturally occurring compounds. Prostaglandin Endoperoxide Analogs,Prostaglandin Endoperoxide Analogues,Synthetic Prostaglandin Endoperoxides,Analogues, Prostaglandin Endoperoxide,Endoperoxide Analogues, Prostaglandin,Endoperoxides, Synthetic Prostaglandin
D011982 Receptors, Prostaglandin Cell surface receptors that bind prostaglandins with high affinity and trigger intracellular changes which influence the behavior of cells. Prostaglandin receptor subtypes have been tentatively named according to their relative affinities for the endogenous prostaglandins. They include those which prefer prostaglandin D2 (DP receptors), prostaglandin E2 (EP1, EP2, and EP3 receptors), prostaglandin F2-alpha (FP receptors), and prostacyclin (IP receptors). Prostaglandin Receptors,Prostaglandin Receptor,Receptor, Prostaglandin,Receptors, Prostaglandins,Prostaglandins Receptors
D001792 Blood Platelets Non-nucleated disk-shaped cells formed in the megakaryocyte and found in the blood of all mammals. They are mainly involved in blood coagulation. Platelets,Thrombocytes,Blood Platelet,Platelet,Platelet, Blood,Platelets, Blood,Thrombocyte
D003645 Death, Sudden The abrupt cessation of all vital bodily functions, manifested by the permanent loss of total cerebral, respiratory, and cardiovascular functions. Sudden Death
D004195 Disease Models, Animal Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases. Animal Disease Model,Animal Disease Models,Disease Model, Animal
D005231 Fatty Acids, Unsaturated FATTY ACIDS in which the carbon chain contains one or more double or triple carbon-carbon bonds. Fatty Acids, Polyunsaturated,Polyunsaturated Fatty Acid,Unsaturated Fatty Acid,Polyunsaturated Fatty Acids,Acid, Polyunsaturated Fatty,Acid, Unsaturated Fatty,Acids, Polyunsaturated Fatty,Acids, Unsaturated Fatty,Fatty Acid, Polyunsaturated,Fatty Acid, Unsaturated,Unsaturated Fatty Acids
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D006834 Hydrazines Substituted derivatives of hydrazine (formula H2N-NH2). Hydrazide

Related Publications

Y Shin, and K J Romstedt, and K Doyle, and M W Harrold, and M A Gerhardt, and D D Miller, and P N Patil, and D R Feller
Effect of trimetoquinol analogs for antagonism of endoperoxide/thromboxane A2-mediated responses in human platelets and rat aorta.
January 1985, The Journal of pharmacology and experimental therapeutics,
Y Shin, and K J Romstedt, and K Doyle, and M W Harrold, and M A Gerhardt, and D D Miller, and P N Patil, and D R Feller
Synthesis and platelet antiaggregatory activity of trimetoquinol analogs as endoperoxide/thromboxane A2 antagonists.
February 1987, Drug design and delivery,
Y Shin, and K J Romstedt, and K Doyle, and M W Harrold, and M A Gerhardt, and D D Miller, and P N Patil, and D R Feller
Synthesis of stable thromboxane A2 analogs: pinane thromboxane A2 (PTA2) and carbocyclic thromboxane A2 (CTA2).
January 1982, Methods in enzymology,
Y Shin, and K J Romstedt, and K Doyle, and M W Harrold, and M A Gerhardt, and D D Miller, and P N Patil, and D R Feller
In vivo pharmacologic profile of YM158, a new dual antagonist for leukotriene D4 and thromboxane A2 receptors.
May 2000, Japanese journal of pharmacology,
Y Shin, and K J Romstedt, and K Doyle, and M W Harrold, and M A Gerhardt, and D D Miller, and P N Patil, and D R Feller
Synthesis of thromboxane A2 analogs.
January 1980, Advances in prostaglandin and thromboxane research,
Y Shin, and K J Romstedt, and K Doyle, and M W Harrold, and M A Gerhardt, and D D Miller, and P N Patil, and D R Feller
Different pharmacologic activities for 13-azapinane thromboxane A2 analogs in platelets and blood vessels.
April 1988, European journal of pharmacology,
Y Shin, and K J Romstedt, and K Doyle, and M W Harrold, and M A Gerhardt, and D D Miller, and P N Patil, and D R Feller
Thromboxane A2 receptors.
October 1995, Journal of lipid mediators and cell signalling,
Y Shin, and K J Romstedt, and K Doyle, and M W Harrold, and M A Gerhardt, and D D Miller, and P N Patil, and D R Feller
Prostaglandin endoperoxide and thromboxane A2 analogs.
January 1985, Advances in prostaglandin, thromboxane, and leukotriene research,
Y Shin, and K J Romstedt, and K Doyle, and M W Harrold, and M A Gerhardt, and D D Miller, and P N Patil, and D R Feller
Syntheses of thromboxane A2 analogs: Thia- and dithiathromboxane A2.
January 1983, Advances in prostaglandin, thromboxane, and leukotriene research,
Y Shin, and K J Romstedt, and K Doyle, and M W Harrold, and M A Gerhardt, and D D Miller, and P N Patil, and D R Feller
Antagonism of thromboxane receptors by diclofenac and lumiracoxib.
December 2007, British journal of pharmacology,
Copied contents to your clipboard!